Biblio
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leuk Res. 2018;74:86-88.
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. 2013.
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget. 2016.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer. 2023.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2019.
Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New Compounds. Clin Lymphoma Myeloma Leuk. 2023.
. Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors. Expert Opin Pharmacother. 2024.
. RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA. Hematol Oncol. 2020.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Cancer. 2023.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020.
Treatment-free remission in chronic myeloid leukemia. Clin Adv Hematol Oncol. 2019;17(12):686-696.
.